Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine.

[1]  A. Holder,et al.  Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. , 2001, Journal of molecular biology.

[2]  J. Langhorne,et al.  Different Regions of the Malaria Merozoite Surface Protein 1 of Plasmodium chabaudi Elicit Distinct T-Cell and Antibody Isotype Responses , 2001, Infection and Immunity.

[3]  J. Palensky,et al.  Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. , 2001, The Journal of infectious diseases.

[4]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[5]  B. Stockinger,et al.  Low CD4+ T cell responses to the C‐terminal region of the malaria merozoite surface protein‐1 may be attributed to processing within distinct MHC class II pathways , 2001, European journal of immunology.

[6]  A. Holder,et al.  Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. , 1999, Journal of molecular biology.

[7]  J. K. Moch,et al.  Passive transfer of growth-inhibitory antibodies raised against yeast-expressed recombinant Plasmodium falciparum merozoite surface protein-1(19). , 1998, The American journal of tropical medicine and hygiene.

[8]  A. Holder,et al.  Antibodies that Inhibit Malaria Merozoite Surface Protein–1 Processing and Erythrocyte Invasion Are Blocked by Naturally Acquired Human Antibodies , 1997, The Journal of experimental medicine.

[9]  Joe D. Cohen,et al.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.

[10]  A. Holder,et al.  Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. , 1996, The Journal of infectious diseases.

[11]  P. Barr,et al.  A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria , 1996, Infection and immunity.

[12]  C. Long,et al.  Plasmodium yoelii yoelii 17XL MSP-1: fine-specificity mapping of a discontinuous, disulfide-dependent epitope recognized by a protective monoclonal antibody using expression PCR (E-PCR). , 1995, Experimental parasitology.

[13]  D. Kaslow,et al.  Immunogenicity and In Vivo Efficacy of Recombinant Plasmodium falciparum Merozoite Surface Protein-1 in Aotus Monkeys , 1995, Molecular medicine.

[14]  A. Holder,et al.  Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. , 1994, Molecular and biochemical parasitology.

[15]  A. Holder.  Proteins on the surface of the malaria parasite and cell invasion , 1994, Parasitology.

[16]  A. Holder,et al.  Immunization against malaria with a recombinant protein , 1994, Parasite immunology.

[17]  A. Holder,et al.  Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1. , 1993, Molecular and biochemical parasitology.

[18]  L. Miller,et al.  The major merozoite surface protein as a malaria vaccine target. , 1993, Parasitology today.

[19]  P. Barr,et al.  A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. , 1992, Journal of immunology.

[20]  A. Holder,et al.  Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. , 1992, Molecular and biochemical parasitology.

[21]  A. Holder,et al.  Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. , 1991, Molecular and biochemical parasitology.

[22]  A. Holder,et al.  A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion- inhibiting antibodies , 1990, The Journal of experimental medicine.

[23]  J. Burns,et al.  A protective monoclonal antibody recognizes an epitope in the carboxyl-terminal cysteine-rich domain in the precursor of the major merozoite surface antigen of the rodent malarial parasite, Plasmodium yoelii. , 1989, Journal of immunology.

[24]  M. Perkins,et al.  Sialic acid-dependent binding of Plasmodium falciparum merozoite surface antigen, Pf200, to human erythrocytes. , 1988, Journal of immunology.

[25]  K. Yamaga,et al.  Plasmodium falciparum: gene structure and hydropathy profile of the major merozoite surface antigen (gp195) of the Uganda-Palo Alto isolate. , 1988, Experimental parasitology.

[26]  G. Hui,et al.  Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Holder,et al.  Processing of the precursor to the major merozoite surface antigens of Plasmodium falciparum , 1987, Parasitology.

[28]  J. Haynes,et al.  Monoclonal antibody characterization of the 195-kilodalton major surface glycoprotein of Plasmodium falciparum malaria schizonts and merozoites: identification of additional processed products and a serotype-restricted repetitive epitope. , 1987, Journal of immunology.

[29]  J. McBride,et al.  Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex. , 1987, Molecular and biochemical parasitology.

[30]  K. Haldar,et al.  Acylation of a Plasmodium falciparum merozoite surface antigen via sn-1,2-diacyl glycerol. , 1985, The Journal of biological chemistry.

[31]  A. Holder,et al.  Protective antigens of rodent and human bloodstage malaria. , 1984, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[32]  T. Daly,et al.  Passive immunization against murine malaria with an IgG3 monoclonal antibody. , 1984, Journal of immunology.

[33]  A. Tait,et al.  Antigens of the erythrocytes stages of the human malaria parasite Plasmodium falciparum detected by monoclonal antibodies. , 1983, Molecular and biochemical parasitology.

[34]  I. McGregor,et al.  Gamma-Globulin and Acquired Immunity to Human Malaria , 1961, Nature.

[35]  J. K. Moch,et al.  Erythrocytic malaria growth or invasion inhibition assays with emphasis on suspension culture GIA. , 2002, Methods in molecular medicine.

[36]  M. Blackman,et al.  Purification of Plasmodium falciparum merozoites for analysis of the processing of merozoite surface protein-1. , 1994, Methods in cell biology.